An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

NCT01945710 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
62
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Limited